Jefferies has increased its price target for Ventas, Inc. from $95 to $98 following the company's Q3 2026 earnings report. This adjustment indicates a slightly more optimistic valuation by the investment firm, which could provide a minor positive sentiment boost for Ventas shares.
Jefferies, an investment firm, has raised its price target for Ventas, Inc. (VTR) from $95 to $98. This change comes after Ventas released its third-quarter 2026 earnings report on October 27, 2026. The updated price target reflects Jefferies' revised valuation assessment of the healthcare REIT. For traders, this is a moderately positive signal, suggesting that a notable investment bank sees slightly more upside in Ventas' stock. While not a major catalyst, it could contribute to short-term positive sentiment and potentially attract some buying interest, though the long-term impact depends on broader market conditions and Ventas' continued performance.